Clinical Trials on Influenza, Human

Total 8064 results

Seqirus

Completed

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children

Influenza Caused by the Novel Influenza A (H1N1) Virus

Australia
IDRI
Defense Advanced Research Projects Agency; Medicago

Completed

H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers

Influenza A Subtype H5N1 Infection

United States
GlaxoSmithKline

Completed

Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults

Haemophilus Influenzae | Streptococcus Pneumoniae

Sweden
GlaxoSmithKline

Terminated

Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine

Haemophilus Influenzae | Streptococcus Pneumoniae

Canada
Seqirus

Completed

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults

Influenza Caused by the Novel Influenza A (H1N1) Virus

Australia
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old

Influenza A Virus, H7N9 Subtype

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals

Influenza A Virus, H7N9 Subtype

United States
University of Witwatersrand, South Africa

Completed

Influenza Vaccine in HIV Infected Children

Influenza With Pneumonia, Influenza Virus Identified

South Africa
Dove Medical Press Ltd
The Affiliated Hospital of Qingdao University

Completed

The Research of Novel Electrolyzed Water Spray to Eradicate Bacteria E-coli and an Attenuated Human Flu Virus

Bacterial Growth | Novel Influenza A (H1N1)

China
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23

Influenza (Healthy Volunteers)

Germany, Finland
Sanofi Pasteur, a Sanofi Company

Completed

Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea

Influenza (Healthy Volunteers)

Korea, Republic of
Hvivo
Pfizer

Completed

Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain

Influenza A H1N1

United Kingdom
Sanofi Pasteur, a Sanofi Company

Terminated

Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Finland
Insight Therapeutics, LLC
Brown University; Case Western Reserve University; Seqirus

Completed

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

Influenza | Influenza-like Illness

United States
Insight Therapeutics, LLC
Brown University; Genentech, Inc.; Case Western Reserve University

Active, not recruiting

Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks

Influenza | Influenza, Human | Influenza -Like Illness

United States
University Hospital, Ghent
CEVAC Core Lab, University Ghent; Max Planck Institute for Infection Biology... and other collaborators

Completed

Study of Biomarkers of Immune Activation Associated With Symptoms and Immune Responses After Influenza Vaccination in Adults

Prevention of Influenza

Belgium
University of Leicester
Sanofi Pasteur, a Sanofi Company; University Hospitals, Leicester; World Health... and other collaborators

Completed

Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness (BELIEVE)

Influenza | Influenza -Like Illness

United Kingdom
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

Pandemic Influenza Disease

Finland, Germany
China Academy of Chinese Medical Sciences
Renmin Hospital of Wuhan University; Children's Hospital of Soochow University and other collaborators

Unknown

Clinical Study of Reduning Injection for the Treatment of Influenza in Children

Influenza in Children
Public Health England

Completed

Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls (Flushed)

Influenza | Vaccination | Influenza Vaccination

United Kingdom
Vaxart

Completed

Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults

Seasonal Influenza B

New Zealand
University Health Network, Toronto

Completed

Adjuvanted Influenza Vaccine in Stem Cell Transplant

Transplantation | Influenza Vaccines
Novartis Vaccines

Completed

Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10

Pandemic Influenza Disease

Italy
David Scheifele
Canadian Institutes of Health Research (CIHR); PHAC/CIHR Influenza Research...

Completed

Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults

H1N1/2009 Influenza

Canada
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008

Seasonal Influenza Vaccine

Germany
University of Nottingham

Completed

Virus Shedding and Environmental Deposition of a Novel Influenza Virus

Novel (H1N1) Influenza

United Kingdom
University of Manitoba
Hoffmann-La Roche

Terminated

Trial Comparing High Versus Standard Dose Oseltamivir in Severe Influenza Infection in ICU (ROSII)

Influenza A Virus

Canada
Taipei Medical University WanFang Hospital

Unknown

Analysis of the Results From Influenza Rapid Test A Positive and H1N1 Real Time RT-PCR

H1N1 Influenza Virus

Taiwan
Seattle Children's Hospital
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age (GRC28)

Inactivated Influenza Vaccine

United States
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008

Seasonal Influenza | Vaccine

Germany
Sinovac Biotech Co., Ltd
Centers for Disease Control and Prevention, China

Completed

Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine

Prevention | Pandemic Influenza
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects

Pandemic Influenza Disease

Italy
University Medicine Greifswald

Active, not recruiting

Adaptive Immune Response to Seasonal Influenza Vaccination (AIGI) ((AIGI))

Seasonal Influenza Vaccination

Germany
Imperial College London
Duke University; RTI International; Defense Advanced Research Projects Agency

Completed

Assessment of Wearable Sensors During Experimental Human Influenza Infection (Sigma Plus)

Influenza A H3N2

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22

Influenza (Healthy Volunteers)

Germany, Finland
Insight Therapeutics, LLC
Brown University; Seqirus

Completed

Adjuvanted Influenza Vaccination Year 2 Follow-On Survey

Influenza | Influenza, Human | Influenza-like Illness

United States
Insight Therapeutics, LLC
Brown University; Sanofi Pasteur, a Sanofi Company; Case Western Reserve University

Active, not recruiting

Recombinant Influenza Vaccination in U.S. Nursing Homes

Influenza | Influenza, Human | Influenza -Like Illness

United States
Henry M. Jackson Foundation for the Advancement...
National Institute of Allergy and Infectious Diseases (NIAID); Leidos Biomedical... and other collaborators

Completed

Evaluation of Psychometric Testing Properties of Severity Symptom Grading Scale of Influenza Infection: Flu-PRO Stage III (FluPRO3)

Influenza | Influenza-like Illness

United States
Sinovac Biotech Co., Ltd

Completed

Study on Combined Vaccination With Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine

Influenza and Pneumonia

China
SAb Biotherapeutics, Inc.
Hvivo

Active, not recruiting

Study of SAB-176 in Healthy Adult Participants

Influenza A H1N1

United Kingdom
The University of Hong Kong

Withdrawn

Novel Assays for Detection of Influenza Virus

Influenza A Virus

Hong Kong
SK Chemicals Co., Ltd.

Completed

Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults

Prevention of Influenza

Korea, Republic of
Johns Hopkins Bloomberg School of Public Health

Completed

Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study

Influenza Virus Vaccine

United States
Indonesia University

Completed

Probiotic and Influenza Vaccination to Reducing Influenza-like Illness Incident in Elderly

Influenza-like Illness

Indonesia
Novartis Vaccines
Novartis Vaccines and Diagnostics (formerly Chiron Vaccines)

Completed

Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults

Influenza Disease; Flu

United States
David Scheifele
Canadian Institutes of Health Research (CIHR)

Completed

Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults Receiving Seasonal Influenza Vaccine

Influenza | H1N1 2009 Influenza

Canada
The University of Hong Kong
Research Grants Council, Hong Kong; Research Fund for the Control of Infectious... and other collaborators

Completed

Direct and Indirect Benefits of Influenza Vaccine Versus Placebo in Healthy Children

Influenza Virus Infection

China
Abbott Biologicals

Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2012/2013 Season

Prophylaxis of Influenza

Germany
Centers for Disease Control and Prevention
University of California, Berkeley

Completed

REDucing Influenza Among University Students, University of California at Berkeley (REDI-US)

Influenza | Influenza-like Illness

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Exploratory Clinical Study of MT-2301

Haemophilus Influenza Type b

Japan

Clinical Trials on Influenza, Human

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations